Zafgen, Inc. (ZFGN) Raised to Sell at ValuEngine

ValuEngine upgraded shares of Zafgen, Inc. (NASDAQ:ZFGN) from a strong sell rating to a sell rating in a report issued on Monday.

Separately, Zacks Investment Research lowered shares of Zafgen from a buy rating to a hold rating in a research report on Friday, September 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $6.38.

Shares of Zafgen (NASDAQ ZFGN) opened at 3.74 on Monday. The stock’s market capitalization is $102.79 million. Zafgen has a one year low of $2.89 and a one year high of $5.46. The company’s 50-day moving average is $3.51 and its 200-day moving average is $3.84.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the previous year, the business earned ($0.55) earnings per share. On average, equities research analysts anticipate that Zafgen will post ($2.23) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Zafgen, Inc. (ZFGN) Raised to Sell at ValuEngine” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/10/19/zafgen-inc-zfgn-raised-to-sell-at-valuengine.html.

In other news, Director Frances K. Heller acquired 10,000 shares of the stock in a transaction that occurred on Friday, October 13th. The shares were purchased at an average cost of $3.90 per share, for a total transaction of $39,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 21.20% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Algert Global LLC purchased a new position in Zafgen in the 2nd quarter valued at $123,000. Parametric Portfolio Associates LLC grew its position in Zafgen by 55.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 10,327 shares during the last quarter. Wells Fargo & Company MN grew its position in Zafgen by 1,290.3% in the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 40,400 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at $259,000. Finally, LMR Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at $299,000. Hedge funds and other institutional investors own 48.52% of the company’s stock.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply